Welcome [Sign In] To track stocks & more, Register

Financial News

Enter symbol(s) Basic Get Symbol Lookup

Kaplan Fox Seeks to Recover Losses for Investors Who Purchased 

Securities of Bristol-Myers Squibb Company

Wednesday June 27, 5:27 pm ET 

NEW YORK, NY--(MARKET WIRE)--Jun 27, 2007 -- On June 20, 2007, Kaplan Fox & Kilsheimer LLP filed a class 

action lawsuit in the United States District Court for the Southern District of New York on behalf of a class (the 

"Class") of all persons who purchased securities of Bristol-Myers Squibb Company ("BMY" or the "Company") 

(NYSE:BMY - News) between March 22, 2006 and August 8, 2006, inclusive (the "Class Period") and alleges 

violations of the federal securities laws by BMY and certain of its present and/or former executives. 

As alleged in the Complaint, on March 22, 2006, BMY announced that it, along with Sanofi-Aventis SA, entered into a 

settlement agreement with Apotex, Inc. ("Apotex") to resolve a patent infringement lawsuit ("Apotex Settlement") 

related to the drug Plavix. The Complaint further alleges that throughout the Class Period, BMY failed to disclose 

material facts regarding the Apotex Settlement including: (1) that BMY had relinquished material rights in connection 

with the settlement, including the right to treble damages; (2) that if the Apotex Settlement was not approved, Apotex 

could flood the market with its generic version of Plavix; and (3) that BMY had negotiated improper side agreements 

in connection with the Apotex Settlement. 

On July 27, 2006, BMY revealed that the Antitrust Division of the United States Department of Justice ("DOJ") was 

conducting a criminal investigation into the Apotex Settlement and, as alleged, as a result of this disclosure, the price 

of BMY's securities declined $1.95 per share, or 7.5%, to close at $24.04 per share. On August 8, 2006, BMY 

disclosed additional material facts regarding the Apotex Settlement. As a result of this disclosure, it is alleged that 

BMY's securities declined $1.56 per share, or approximately 7%, to close at $21.21 per share. 

The Complaint also alleges that on May 10, 2007 BMY issued a press release disclosing that the Company agreed to 

plead guilty to federal charges of making false statements to a government agency in connection with the Apotex 

Settlement. 

If you are a member of the proposed Class, you may move the court no later than August 27, 2007 to serve as a lead 

plaintiff for the Class. You need not seek to become a lead plaintiff in order to share in any possible recovery. 

Plaintiff seeks to recover damages on behalf of the Class and is represented by Kaplan Fox & Kilsheimer LLP. Our 

firm, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience 

in prosecuting investor class actions and actions involving financial fraud. For more information about Kaplan Fox & 

Kilsheimer LLP, or to review a copy of the complaint filed in this action, you may visit our website at 

www.kaplanfox.com. 

If you have any questions about this Notice, the action, your rights or your interests, please e-mail us at 

mail@kaplanfox.com or contact: 

Contact:

 Contacts: 

Press Release Source: Kaplan Fox & Kilsheimer LLP

Yahoo! My Yahoo! Mail Make Y! your home page Web Search

Welcome, ben_heiss

[Sign Out, My Account]

Finance Home -

Help

Search:

Kaplan Fox Seeks to Recover Losses for Investors Who Purchased Securities of Bristol-... Page 1 of 2

http://biz.yahoo.com/iw/070627/0272054.html?printer=1 6/28/2007

Case 1:07-cv-05867-PAC Document 12-3 Filed 08/27/2007 Page 1 of 2
Copyright © 2007 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Ad Feedback 

Copyright © 2007 Marketwire. All rights reserved. All the news releases provided by Marketwire are copyrighted. Any forms of copying other than an 

individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, 

including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form. 

 

 Frederic S. Fox 

 Joel B. Strauss 

 Jeffrey P. Campisi 

 KAPLAN FOX & KILSHEIMER LLP 

 805 Third Avenue, 22nd Floor 

 New York, NY 10022 

 (800) 290-1952 

 (212) 687-1980 

 Fax: (212) 687-7714 

 E-mail address: Email Contact

 

 Laurence D. King 

 KAPLAN FOX & KILSHEIMER LLP 

 555 Montgomery Street, Suite 1501 

 San Francisco, CA 94111 

 (415) 772-4700 

 Fax: (415) 772-4707 

 E-mail address: Email Contact

 

Source: Kaplan Fox & Kilsheimer LLP

Kaplan Fox Seeks to Recover Losses for Investors Who Purchased Securities of Bristol-... Page 2 of 2

http://biz.yahoo.com/iw/070627/0272054.html?printer=1 6/28/2007

Case 1:07-cv-05867-PAC Document 12-3 Filed 08/27/2007 Page 2 of 2